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Spontaneous breathing trialAbstract Background: Prediction of weaning success remains a major clinical challenge. Cardio-
vascular dysfunction could be a major underlying mechanism of weaning failure. Recent data sug-
gest that BNP; a marker for cardiovascular dysfunction, may predict the outcome of weaning from
assisted mechanical ventilation. BNP variations during spontaneous breathing trial may be of pre-
dictive value concerning the outcome of weaning process.
Objective: To evaluate the role of BNP levels measured during a 2 h. SBT as a predictive value
for weaning outcome.
Method: A prospective observational study included forty patients on mechanical ventilation
who underwent an SBT. Echocardiography was done 2 h, before SBT and sampling of BNP was
performed immediately before and at the end of SBT to determine the predictive value of BNP.
Results: Patients were divided according to the result of the 2-h SBT into 3 groups: SBT failure
[8 pts.], extubation success [25 pts.] and extubation failure [7 pts.]. The BNP level was signiﬁcantly
higher in SBT failure and extubation failure groups after SBT than before SBT while it was signiﬁcantly
lower in the extubation success group after SBT than before SBT with a p-value of 0.004. It was found
that both extubation and SBT failure groups had signiﬁcantly larger percent increase in BNP level
unlike the extubation success group who had signiﬁcantly percent decrease in the BNP level with a
p-value <0.001. The area under the ROC curve was 0.96. A change of BNP level <20% from baseline
had the best combination of sensitivity [85.71%], speciﬁcity [90.91%], positive [96.77%] and negative
[66.67%] predictive values and diagnostic accuracy [90%] in predicting extubation failure.
Conclusion: BNP level variation during SBT may improve the predictive value of the trial on wean-
ing outcome.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.
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Liberating a patient from mechanical ventilation remains a sig-
niﬁcant challenge for clinicians [1]. Complications of invasive
mechanical ventilation increase with the duration of ventilator
dependence [2]. Patients should therefore be weaned from
mechanical ventilation as quickly as possible. However, both
delayed and premature weaning may be harmful [2,3]. The
2 h. spontaneous breathing trial (SBT) is currently the most
accurate index for predicting weaning success, but the extuba-
tion failure rate is still high (15–20%) in patients who have
passed SBTs [1]. The causes and pathophysiology underlying
weaning failure is complex [4]. The relative weight of the differ-
ent factors involved is not completely understood. Cardiac
function and, more importantly, volume status may play a
key role in this setting [5]. In critically ill patients, however,
it is difﬁcult to detect cardiovascular dysfunction in the
dynamic process of weaning using the traditional methods
such as echocardiography, cardiac scintiscan and pulmonary
artery catheterization that are either operator-dependent, lack-
ing sensitivity, not available at the bedside, or invasive [6]. B-
type natriuretic peptide (BNP) is a 32-amino acid protein
released from the cardiac ventricles in response to myocardial
stretch [7]. BNP is the most powerful hormonal predictor of
left-ventricular dysfunction, and its plasma level has been cor-
related to left-ventricular ﬁlling pressures [8]. Plasma BNP lev-
els are elevated in acute congestive heart failure [9] and right
ventricular dysfunction [10].
Aim of the work
To determine whether BNP levels measured during a 2 h. SBT
could improve the predictive value for weaning outcome.
Patients and methods
Patients
The study protocol was approved by the local ethics commit-
tee. We randomly and prospectively enrolled forty mechani-
cally ventilated patients admitted consecutively to the critical
care department; faculty of medicine-Cairo university hospital;
from May 2010 till June 2011. Informed consent was given by
a close relative (ﬁrst degree).
Inclusion criteria
Patients being considered for liberation from mechanical ventila-
tion support for the ﬁrst time were enrolled in our study. To be
enrolled in our study; patient needed to show improvement or
resolution of the underlying causes of Respiratory failure indi-
cated by PaO2P 60 mmHg at FiO26 40% and a PEEP6 5 cm
H2O, GCSP 13, temperature < 38 C and hemodynamically
stable with a mean blood pressureP 65 mmHg and without
the use of vasoactive agents for at least 24 h.
Exclusion criteria
Patients with left ventricular failure, right ventricular fail-
ure, pulmonary hypertension, aortic valve disease, atrialﬁbrillation, renal impairment, hyperthyroidism, cerebrovascu-
lar strokes, anemia, liver cirrhosis, tracheostomy and obesity
were excluded from the study as these conditions may be asso-
ciated with increased BNP levels.
All included patients were subjected to the following:
1. Full Clinical Evaluation: Including demographic data,
full medical history of present illness, pre-existing co-
morbidity and full clinical examination including base-
line hemodynamics.
2. Laboratory Investigations:
 Routine labs: CBC (complete blood count): Hemo-
globin, Hematocrit, White blood cells and platelet
count, Coagulation proﬁle: PT (prothrombin time),
PC (prothrombin concentration), INR and PTT (par-
tial thromboplastin time), Liver function tests: ALT
(Alanine aminotransferase), AST (Aspartate amino-
transferase), BIL (bilirubin) total and direct and
albumin, Kidney Function Tests: Na, K, Creatinine
and Urea, Thyroid proﬁle (freeT3 freeT4, and TSH)
and Serum electrolytes (Sodium, Potassium & Cal-
cium). These routine Labs were withdrawn on day
1 of the study.
 Serial Arterial blood gases.
 BNP measurement: This was done by the use of
BNP-32 (human) EIA kit provided by Phoenix phar-
maceuticals, INC. This kit is designed to detect a spe-
ciﬁc peptide and its related peptides based on the
principle of competitive enzyme immunoassay.Blood sampling
Blood samples were collected from patients before and after
SBT as follows: 7 ml of venous blood was drawn into tubes
containing EDTA for anticoagulation & aprotinin (protease
inhibitor), each tube was gently rocked several times immedi-
ately after collection of blood to prevent blood clotting and
inhibit the activity of proteases, then centrifuged for 15 min
at 4 C and plasma was collected in eppendorf tubes and kept
at 70 C till analysis within 4 h using a fully automated micro
particle enzyme immunoassay by the use of the BNP-32
(human) EIA kit provided by phoenix pharmaceutical INC.Principle of the assay
The immunoplate in the kit is pre-coated with secondary anti-
body and the non-speciﬁc binding sites are blocked. The sec-
ondary antibody can bind to the Fc fragment of the primary
antibody (peptide antibody) whose Fab fragment will be com-
petitively bound by both biotinylated peptide and peptide
standard or targeted peptide in samples. The biotinylated pep-
tide interacts with streptavadine-horseradish peroxidase (SA-
HRP) which catalyzes the substrate solution. The intensity of
the yellow is directly proportional to the amount of biotinyla-
ted peptide-SA-HRP complex but inversely proportional to
the amount of the peptide in standard solutions or samples.
This is due to the competitive binding of the biotinylated
peptide with the standard peptide or samples to the peptide
antibody (primary antibody). A standard curve of known
concentration was established accordingly. The unknown
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to this standard curve.
Assay procedure
The kit was stored at 4 C and all kit components were allowed
to return to room temperature (20–23 C) before use (25–
45min). The assay buffer concentrate was diluted with
950 ml of distilled water to dilute or reconstitute all other
reagents in this kit and samples. Centrifugation of the standard
peptide was done with l ml of the diluted assay buffer. Rehy-
dration of the primary antibody was done with 5 ml of diluted
assay buffer. Rehydration of biotinylated peptide was done
with 5 ml of diluted buffer. Centrifugation of the standard
peptide was done with l ml of the diluted assay buffer. Centri-
fugation & rehydration of the positive control were done with
200 ml of diluted assay buffer. Two wells were left empty as a
blank. 50 ll of each of the prepared standards was dispensed
into designated wells. 25 ll of rehydrated primary antibody
was added into each well except the blank well. 25 ll of rehy-
drated biotinylated peptide was added into each well except
the blank well. The immunoplate was sealed with acetate plate
sealer (APS) and incubated for 2 h at room temperature. The
SA-HRP vial was centrifuged for 5 s and 12 ml of SAHRP
was added to 12 ml of diluted assay buffer to make SA-HRP
solution. 100 ll of SA-HRP solution was added into each well.
100 ll of TMB substrate solution was added into each well.
100 ll of 2 N HCl was added into each well to stop the reac-
tion. The wells were left till their color changed from blue to
yellow before reading. The immunoplate was loaded onto a
Micro-titer Plate Reader. Absorbance was read at 450 nm.
Calculation of results
The standard curve was plotted on a semi-log graph paper. It
was constructed by plotting the known concentrations of stan-
dard peptide on the log scale and its corresponding O.D. reading
on the linear scale. The standard curve shows an inverse relation-
ship between peptide concentrations and the corresponding
absorbance. As the standard concentration increases, the yellow
color decreases, thereby reducing the O.D. absorbance.
1. Standard 12 leads ECG: to detect ischemia and to
exclude atrial ﬁbrillation.
2. Imaging studies: Echocardiography; was done for all
patients 2 h, before SBT to assess Left ventricular
dimensions & contractility. The left ventricular ejection
fraction (LVEF) was calculated by the biplane modiﬁed
Simpson’s method from the apical 4-chamber view by
an echo cardiographer who was blind to patient wean-
ing outcome and BNP levels.
3. Protocol of the spontaneous breathing trial:Whenmechan-
ically ventilated patients were placed on low pressure sup-
port (6–10 cmH2O) for at least 2 h,mechanical ventilation
was stopped and the patient was allowed to breathe spon-
taneously through at T-tube (SBT) with the same Fio2.
On the basis of the clinical ﬁndings, patients were subdivided
according to the outcome of the 2-h SBT into 3 groups: Group
A: SBT failure, Group B: extubation success and Group C:
extubation failure.Patients were considered to have failed SBT if they devel-
oped any of the following during the 2-h SBT [37]:
1. Respiratory frequencyP 35 breaths per minute.
2. Arterial oxygen saturation < 90%.
3. Heart rateP 140 beats per minute or a sustained
increase or decrease in heart rate > 20%.
4. Systolic blood pressure > 180 mm Hg or < 90 mm Hg.
5. Thoraco-abdominal dys-synchrony, agitation, diapho-
resis, or anxiety.
Patients who had none of these features at the end of the
SBT were subsequently extubated. After extubation, the
patients were closely monitored for 48 h. Patients were re-intu-
bated if they developed one of the following signs:
1. Hypoxemia: SaO2 < 90% or PaO2 < 60 mmHg at
FIO2 > 50%.
2. Respiratoryacidosis: PH< 7.30withPCO2 > 50 mmHg.
3. Clinical signs of respiratory distress including at least
one of the following: Thoraco-abdominal desynchrony,
retraction of intercostal spaces, use of the accessory
muscles, agitation, increasing of the respiratory rate >
35 bpm and sustained increase in heart rate > 20%.
Statistics
Date were statistically described in terms of range, mean, stan-
dard deviation (±SD), median, frequencies (number of cases)
and percentages when appropriate. Comparison of quantita-
tive variables between the study groups was done using Mann
Whitney U test for independent samples. For comparing cate-
gorical date, Chi square (v2) test was performed. Exact test was
used instead when the expected frequency is less than 5. Recei-
ver operator characteristic (ROC) analysis was used to deter-
mine the optimum cut off value for the studied diagnostic
markers. Correlation between various variables was done
using Spearman rank correlation equation for non-normal
variables. A probability value (p value) less than 0.05 was con-
sidered statistically signiﬁcant. Statistical calculations were
done using computer program Microsoft Excel 2003 (Micro-
soft Corporation, NY, USA) and SPSS (Statistical Package
for the Social Science; SPSS Inc., Chicago, IL, USA) version
15 for Microsoft Windows.
Results
1. Demographic and baseline clinical characteristics of the
patient population on admission (Table 1).
2. Classiﬁcation of patients according to SBT trial (Table 2).
3. Clinical characteristics of different study groups (Table 3).
4. BNP level before and after SBT in different study groups:The
BNP level was signiﬁcantly higher in SBT failure and extuba-
tion failure groups after SBT than before SBT while it was
signiﬁcantly lower in the extubation success group after
SBT than before SBT with a p-value of 0.004 (Table 4).
5. The mean percent change in plasma BNP level during 2-h.
SBT:The mean percent change in BNP level during the 2-h.
SBT in the extubation success group showed signiﬁcantly
Table 1 Demographic and baseline clinical characteristics of
the patients on admission.
Characteristics Patients groups
Number of patients 40
Age; mean ± SD in years (range) 48.80 ± 10.19(28–69)
Male:Female sex (ratio & percentage) 26:14 (65:35%)
Causes of ARF (number & percentage)
ARDS 12 (30%)
COPD 4 (15%)
Pneumonia 12 (30%)
Sepsis 12 (30%)
Comorbidity (number & percentage)
Hypertension 28 (70%)
Diabetes Mellitus 19 (47%)
Ischemic Heart Disease 8 (20%)
Risk factor (number & percentage)
Smoking 24 (60%)
Table 2 Classiﬁcation of patients according to SBT trial.
Groups SBT failure SBT success
Extubation failure Extubation Success
Number 8 7 25
Percentage (%) 20% 17.5% 62.5%
674 S.E. Maraghi et al.percent decrease in the BNP level [24.987%] than in the
SBT failure [36.723%] and extubation failure [34.226%]
groups who showed signiﬁcantly percent increase with a
p-value < 0.001 (Table 5).
6. Correlation between BNP level and LVEF% in different
study groups:No signiﬁcant correlation was found between
BNP before SBT and LVEF% (Table 6).Table 3 Clinical characteristics of different study groups.
Characteristics Study groups
SBT Failure
Number of patients 8
Age; mean ± SD in years 50 ± 9.49
Gender; Male:Female 6:2
Causes of ARF (number & percentage)
ARDS 2 (16%)
COPD 1 (25%)
Pneumonia 1 (8.33%)
Sepsis 5 (41.6%)
Comorbidity (number & percentage)
Hypertension 7 (25%)
Diabetes Mellitus 3 (15.8%)
Ischemic Heart Disease 0 (0%)
Risk Factor (number & percentage)
Smoking 6 (25%)
APACHE II Score (mean ± SD) 18 ± 1.07
Mechanical ventilation days (mean ± SD) 15.4 ± 6.37. ABG before and after SBT in different study groups:There
was a signiﬁcant decrease in PO2 level and oxygen satura-
tion in both SBT failure and extubation failure group after
the SBT trial while there was no signiﬁcant change in the
ABG parameters in the Extubation success group (Table 7).
8. Predictive value of the percent change in BNP on extuba-
tion outcome:To determine the value of percent change in
the BNP level during the 2-h. SBT that best predicts the
extubation outcome; we analyzed the data from the 32
patients who passed the 2-h. SBT using the ROC curve.
The area under the ROC curve was 0.96. A change of
BNP level < 20% from baseline had the best combination
of sensitivity [85.71%], speciﬁcity [90.91%], positive
[96.77%] and negative [66.67%] predictive values and diag-
nostic accuracy [90%] in predicting extubation failure
(Fig. 1).
Discussion
Weaning patients from mechanical ventilation continues to
pose a challenge to clinicians for its complications with time
[11]. A successful weaning from mechanical ventilation
depends not only on adequate respiratory strength and endur-
ance but also on optimal performance of other organs includ-
ing the heart. The patient cardiovascular function may be
compromised by alterations in lung volume and intrathoracic
pressure during withdrawal of mechanical ventilation and
may be an important cause of weaning failure [12].
Cardiovascular dysfunction is mainly associated with an
increase in cardiac preload and afterload caused by intra-tho-
racic pressure shift and an increase in catecholamine secretion
and work of breathing [13].
Diagnosing left ventricular dysfunction in patients who fail
to wean is clinically difﬁcult using the traditional methods such
as echocardiography, cardiac CT scan and pulmonary artery
catheterization that are either operator-dependent, lack sensi-
tivity, not available at the bedside and invasive. The use of pul-
monary artery catheter remains the gold standard to identifyp-Value
Extubation Failure Extubation Success
7 25
54 ± 9.25 46 ± 10.35 0.208
5:2 15:10 0.686
2 (16%) 8 (66.6%) 0.707
2(50%) 1 (25%) 0.170
1 (8.33%) 10 (83.3%) 0.268
4(33.3%) 3 (25%) 0.724
4 (14.3%) 17 (60.7%) 0.414
5 (26.3%) 11 (57.9%) 0.359
2 (25%) 6 (75%) 0.276
5 (20.8%) 13 (54.2%) 0.407
17.43 ± 0.98 18.24 ± 1.88 0.512
12.8 ± 7.4 9.5 ± 4.2 0.78
Table 4 BNP level before and after SBT in different study groups.
BNP level (pg/ml) Study groups p-Value
SBT failure Extubation failure Extubation success
Before SBT 853.1 ± 471.3 592.5 ± 271.7 543 ± 131.1 0.173
After SBT 1166.38 ± 189.7 795.29 ± 256.37 407.32 ± 202.41 0.004
Table 5 The mean percent change in plasma BNP level during 2-h. SBT.
Study groups p-Value
SBT failure Extubation failure Extubation success
Percent change [increase/decrease] 36.723% [Inc.] 34.226% [Inc.] 24.987% [dec.] <0.001
Table 6 correlation between BNP level before SBT&
LVEF%.
BNP before SBT LVEF% p-Value
SBT failure 853.1 ± 471.3 58.7 ± 3.47 0.18
Extubation failure 592.5 ± 271.7 60.3 ± 5.33 0.21
Extubation success 543 ± 131.1 62.5 ± 7.9 0.14
Figure 1 Predictive value of percent change in BNP.
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pulmonary artery occlusion pressure can be difﬁcult in dys-
pneic patients [15]. Echocardiography may help to identify
heart failure during weaning but lack of trained personnel
and the needs for a good echocardiographic window limit its
application [16].
The 2 h spontaneous breathing trial (SBT) is currently the
most accurate index for predicting weaning success, but the
extubation failure rate is still high (15–20%) in patients who
have passed SBTs [1].
In patients on positive pressure ventilation, cardiovascular
dysfunction may be difﬁcult to detect [17]. During the negative
pressure SBT, venous return is augmented, left ventricular
trans-mural pressure and after load may also be increased
[18]. These stresses placed on the heart during SBT may
unmask subclinical cardiovascular dysfunction. Lemaire
et al. (1988) studied 15 patients with cardiovascular disease
and chronic obstructive pulmonary disease. They found that
the pulmonary capillary wedge pressure was normal before
SBT but increased signiﬁcantly after unsuccessful SBT [5].
B-type natriuretic peptide (BNP) is a plasma neurohor-
mone composed of 32 amino acid protein secreted by ventric-Table 7 ABG before and after SBT in different study groups.
ABG Parameter Study Groups
SBT failure Extubation
Before SBT After SBT p-Value Before SBT
PH 7.38 ± 0.04 7.35 ± 0.03 0.16 7.42 ± 0.0
Po2 (mm Hg) 87.4 ± 18.6 74.6 ± 20.1 0.01 90 ± 17
PCo2 (mm Hg) 37.3 ± 6.3 39.4 ± 7.5 0.60 39 ± 6
Sat % 95.13 ± 2.3 87 ± 0.89 0.02 93 ± 1.8ular cardiomyocytes in response to myocardial stretch [7].
Alternative sites for secretion are atria and brain. Plasma
BNP levels are elevated in patients with left ventricular dys-
function [8], acute congestive heart failure [9], and right ven-
tricular dysfunction [10]. BNP is secreted in response tofailure Extubation success
After SBT p-value Before SBT After SBT p-Value
3 7.33 ± 0.03 0.14 7.45 ± 0.05 7.45 ± 0.03 0.34
78 ± 14 0.02 96 ± 25 94 ± 20 0.82
45 ± 9.2 0.41 36 ± 4.1 35 ± 4.3 0.68
85 ± 0.82 0.03 97.0 ± 0.82 96.8 ± 1.05 0.51
676 S.E. Maraghi et al.different stimuli particularly volume overloads and increased
cardiac wall stretch [7]. BNP is a sensitive and speciﬁc serum
marker for cardiovascular dysfunction as it is correlated to left
ventricular ﬁlling pressure [8].
Two B-type natriuretic peptides are detectable in the circu-
lation after proteolysis of a precursor molecule [proBNP]:
BNP (Brain natriuretic peptide) and NT-proBNP (amino-ter-
minal portion of proBNP). Their circulating half-live is 20
and 120 min, respectively [9]. Both are considerably high in
acute and chronic heart failure [19].
Since cardiac dysfunction can cause weaning failure in
patients on mechanical ventilation; we aimed in this study to
investigate whether BNP level may enhance the predictive
value of a 2-h. SBT for successful extubation. We hypothesized
that BNP could be an alternative to pulmonary catheter or
echocardiography in SBT. For this purpose we studied 40
mechanically ventilated patients recovering from respiratory
failure to determine the predictive value of BNP measured dur-
ing a 2-h. SBT on weaning outcome. The studied patients were
recruited within the period between May 2010 and June 2011
from the critical care department; Cairo university. Patients
were divided according to the result of the 2-h SBT into 3
groups: SBT failure [8 pts.], extubation success [25 pts.] and
extubation failure [7 pts.].
Age and sex determine 30% of the variability in BNP levels
[20]; in healthy subjects [21] and in those with heart failure [22],
BNP levels increase with age. Similarly; the BNP level is 25–
50% higher among women as compared with men [21]. This
difference is probably because of hormonal effects [estrogen
stimulates the secretion of BNP] [23]. In our study we did
not ﬁnd any statistically signiﬁcant difference between the dif-
ferent studied groups as regards age and gender (p-value 0.208
& 0.686, respectively). Our results helped to nullify the age as
an important factor inﬂuencing increase of BNP concentra-
tions in ICU patients. This was in agreement with a study done
by Jung et al. (2008) who studied ﬁfty-two patients recovering
from acute respiratory failure [24]. He found no signiﬁcance
for age and gender in both testing and validation groups (p-
value 0.41, 0.07 & 0.25). Our result was contradicted by a
study done by Principi et al. (2009) [25] who studied thirty
patients admitted to ICU; they found that age was the only
variable that showed a statistically signiﬁcant difference
between various studied groups especially in the heart failure
group (p< 0.05).
Our study did not ﬁnd any signiﬁcant difference for the
APACHE II score among the three studied groups with a p-
value of 0.512 (table 3). This result coincides with the study
done by Principi et al. (2009) who found no signiﬁcant differ-
ence between the studied groups as regards the APACHE II,
SAPS II and MODS score [25]. Similarly; Gang et al. (2013)
studied 29 postoperative mechanically ventilated patients for
N-terminal pro-hormone BNP and found no signiﬁcant differ-
ence between the studied groups regarding age, sex, body mass
index and APACHE II score (p> 0.05) [26].
The cause of respiratory failure in the studied groups was
attributed to ARDS, COPD, pneumonia and sepsis. Although
we did found any statistically signiﬁcant difference between the
studied groups regarding the cause (p-value 0.707, 0.170, 0.268
& 0.724 respectively); SBT and extubation failure were high
among patients with sepsis. This may be related to the fact that
elevation of BNP in sepsis and septic shock is correlated with
the severity of cardiac dysfunction associated with sepsis [27]and could be explained in part by the induction of cytokines
such as IL-1ß and IL-6 and also by impaired neutral endopep-
tidase activity [28].
BNP has proved to be a powerful diagnostic [29] and prog-
nostic marker [30] for heart failure, whether systolic, diastolic,
valvular or ischemic. BNP is the most reliable hormonal mar-
ker for left ventricular dysfunction and its plasma levels corre-
late closely with indices of systolic function in patients with
stable and decompensated heart failure [31]. In right heart dis-
ease BNP is elevated in the subgroups with pulmonary hyper-
tension [32].
Echocardiography was done in our study 2 h. before SBT
to exclude left ventricular dysfunction by estimating ejection
fraction to alleviate the role of heart failure in elevation of
BNP levels. Our study did not ﬁnd any signiﬁcant correlation
between BNP and LVEF in the three studied groups. This is in
concordance with the study done by Jung et al. (2008) who
studied ﬁfty-two patients recovering from acute respiratory
failure to determine the predictive value of BNP; they found
no signiﬁcant correlation between EF% 2 h before SBT and
BNP level [24].
In this study, we investigated whether BNP levels may
enhance the predictive value of a 2 h. SBT for successful extu-
bation. We found that patients who were extubated success-
fully have much lower BNP level after SBT than before SBT
unlike both SBT and extubation failure groups who found to
have higher BNP with a p-value of 0.004.
Our ﬁndings were similar to the results of Jung et al., 2008
who found that patients who were extubated successfully had
much smaller plasma BNP level during 2 h. SBT than patients
who failed extubation in both testing and validation group
(225 vs. 305 & 394 vs. 401 pg/ml respectively) [24]. Similarly;
Chien et al. (2008) found patients who required re-intubation
after a previous successful SBT had a higher increase of
BNP than patients who were successfully extubated (471 vs.
174 with a p-value > 0.05) [33].
Recently our results were validated by a study done by
Gang et al. (2013) who evaluated the relationship between
NT-pro BNP and weaning outcomes and its ability to predict
weaning success in cancer patients with pulmonary complica-
tions; he found that plasma NT-proBNP was signiﬁcantly
higher in the weaning failure group than in the weaning
success group (829 vs. 345 ng/L respectively with a p-value
0.041) [26].
Another Study by Grasso et al. (2007) evaluated the useful-
ness of serial Plasma NT-proBNP assays for detecting acute
cardiac dysfunction during weaning failure in difﬁcult to-wean
COPD patients. Baseline NT-proBNP levels were signiﬁcantly
higher in patients with cardiac dysfunction and increased sig-
niﬁcantly at the end of the T-piece trial only in those patients
(median 12.733, p-value < 0.05) [34].
At 2006 Mekontso-Dessap studied 102 patients during
weaning from mechanical ventilation and found that BNP ele-
vation before weaning was an independent factor for weaning
failure [35]. However, despite a good prediction of SBT out-
come, baseline BNP did not signiﬁcantly differ between
patients with successful and those failing weaning. The same
was found by Chien et al. (2008) who showed no difference
in the baseline BNP levels but the extubation failure group
had a signiﬁcantly greater increase in BNP at the end of the
2 h. T piece trial than the extubation success group with a
p-value < 0.001 [33].
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BNP level during the 2-h. SBT that best predicts the extubation
outcome. We analyzed the data from the 32 patients who passed
the 2-h. SBT and found that both extubation and SBT failure
groups had signiﬁcantly larger percent increase in BNP level,
indicating inadequate cardiac reserve which might contribute
to subsequent respiratory insufﬁciency and re-intubation unlike
the extubation success group who had signiﬁcantly percent
decrease in BNP level with a p-value < 0.001.
We also evaluated the percent change in the BNP level that
best predicts the extubation outcome using the ROC curve.
The area under the ROC curve was 0.96. It was found that
change of BNP level < 20% from baseline had the best com-
bination of sensitivity [85.71%], speciﬁcity [90.91%], positive
[96.77%] and negative [66.67%] predictive values and diagnos-
tic accuracy [90%] in predicting extubation failure.
Our ﬁndings were in agreement with a study done by Jung
et al.(2008) [24] who found no difference in the baseline BNP
levels, but the median percent change in the plasma BNP level
during the 2-h. SBT in the extubation success group was signif-
icantly smaller than those in SBT and extubation failure
groups with a p-value < 0.001. The area under the ROC curve
was 0.93 and the increase of <20% during SBT had the best
combination of sensitivity, speciﬁcity, positive and negative
predictive values and diagnostic accuracy in predicting extuba-
tion success (91%, 88%, 70% & 91%).
In a study of 102 patients during weaning from mechanical
ventilation by Mekontso-Dessap et al. (2006), they found that
despite baseline BNP levels being associated with weaning fail-
ure and longer weaning duration, the change of BNP level dur-
ing 1-h. SBT could not differentiate between patients of
extubation success and extubation failure [35]. This ﬁnding
contradicts ours but this can be explained by; the sampling
interval for BNP in our study was longer (2 h.) than in this
study which is 1 h. This emphasizes that duration of SBT
may be of great importance owing to the half life time of
BNP as it might not begin to increase until the patients have
been on SBT for a longer period of time. A cutoff value of
275 pg/ml was speciﬁc for separating patients with successful
versus failed weaning (sensitivity [83%], speciﬁcity [90%], posi-
tive [93%] and negative [79%] predictive value). Area under
the curve to predict weaning failure was 0.89.
Another Study by Chien et al. (2008) [33] found no differ-
ence in the baseline BNP levels but the extubation failure
group had a signiﬁcantly greater increase in BNP at the end
of 2-h. SBT than the extubation success group (32.7% vs.
0.69%, p< 0.001). An increase of BNP < 20% was validated
in an independent cohort as improving the prediction of extu-
bation success to 95% from 78% using T-piece trial.
Our results were in agreement with a study done by Lluis
et al. (2011) [36] who studied 100 patients on MV for more
than 48 h. who underwent a SBT. An increase of BNP showed
a diagnostic and prognostic accuracy for heart failure as the
cause of weaning failure of 88.9% (p-value < 0.001).
Conclusion
Measurements of BNP and its relative changes could be a use-
ful biomarker augmenting the value of SBT in prediction of
weaning outcome.Conﬂict of interest
None declared.
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